We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
Cap. Flow
+$34M
Cap. Flow %
12.86%
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45

Top Buys

Rank Stock Value
1
DTM icon
DT Midstream
DTM
+$1.85M
2
DK icon
Delek US
DK
+$898K
3
SMG icon
ScottsMiracle-Gro
SMG
+$843K
4
VLO icon
Valero Energy
VLO
+$783K
5
FMC icon
FMC
FMC
+$709K

Top Sells

Rank Stock Value
1
COR
Coresite Realty Corporation
COR
+$1.67M
2
XLRN
Acceleron Pharma
XLRN
+$601K
3
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$448K
5
TVTX icon
Travere Therapeutics
TVTX
+$434K

Sector Composition

Rank Sector Weight
1 Real Estate 22.39%
2 Healthcare 18.38%
3 Energy 15.88%
4 Materials 14.07%
5 Utilities 13.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
226
Immunovant
IMVT
$7.99B
$191K 0.07%
22,435
+2,641
+13% +$21.8K
MGTX icon
227
MeiraGTx Holdings
MGTX
$1.09B
$191K 0.07%
8,032
-5,975
-43% -$114K
ERAS icon
228
Erasca
ERAS
$6.3B
$190K 0.07%
+12,213
New +$209K
KRTX
229
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$190K 0.07%
1,451
-193
-12% -$24.9K
ISEE
230
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$190K 0.07%
11,360
-22,931
-67% -$376K
IMCR icon
231
Immunocore
IMCR
$1.7B
$189K 0.07%
5,523
+164
+3% +$5.94K
PTGX icon
232
Protagonist Therapeutics
PTGX
$8.8B
$189K 0.07%
5,521
+351
+7% +$11.1K
MRNS
233
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$189K 0.07%
15,932
+4,597
+41% +$53.1K
MIRM icon
234
Mirum Pharmaceuticals
MIRM
$6.84B
$188K 0.07%
11,817
-167
-1% -$2.6K
KURA icon
235
Kura Oncology
KURA
$826M
$187K 0.07%
13,354
+4,263
+47% +$69.1K
MRSN
236
DELISTED
Mersana Therapeutics
MRSN
$186K 0.07%
1,199
+632
+111% +$123K
MRUS
237
DELISTED
Merus
MRUS
$186K 0.07%
5,843
-3,548
-38% -$100K
GRTS
238
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$184K 0.07%
14,346
-6,491
-31% -$71.9K
AVIR icon
239
Atea Pharmaceuticals
AVIR
$361M
$183K 0.07%
20,481
+11,549
+129% +$180K
LITS
240
Lite Strategy Inc
LITS
$33M
$183K 0.07%
3,422
+181
+6% +$10.1K
QNCX icon
241
Quince Therapeutics
QNCX
$18.9M
$183K 0.07%
72
+50
+227% +$305K
INBX
242
DELISTED
Inhibrx, Inc. Common Stock
INBX
$183K 0.07%
4,200
-4,495
-52% -$180K
ANAB icon
243
AnaptysBio
ANAB
$1.54B
$182K 0.07%
5,235
-3,302
-39% -$105K
KDNY
244
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$182K 0.07%
11,158
-1,474
-12% -$21K
RLAY icon
245
Relay Therapeutics
RLAY
$3.99B
$181K 0.07%
5,885
-328
-5% -$10.4K
CCCC icon
246
C4 Therapeutics
CCCC
$393M
$180K 0.07%
5,589
+546
+11% +$21.6K
GOSS icon
247
Gossamer Bio
GOSS
$100M
$180K 0.07%
15,932
-8,178
-34% -$97.1K
IDYA icon
248
IDEAYA Biosciences
IDYA
$3.48B
$180K 0.07%
7,622
-2,053
-21% -$47.7K
FDMT icon
249
4D Molecular Therapeutics
FDMT
$515M
$179K 0.07%
8,140
+883
+12% +$21.6K
PHAT icon
250
Phathom Pharmaceuticals
PHAT
$930M
$179K 0.07%
9,080
+2,930
+48% +$69K
8 9
10
11 12

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.

Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.

By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.

  • Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
  • Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
  • Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
  • Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
  • Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
  • Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
  • Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.